Pharmafile Logo

toothbrush

Dave Miller on Biotechs image

Dave W. Miller interviewed by Paige McGarry on the unique challenges faced by biotech companies

HealthEconomics.com interviews David W. Miller, CEO of Genesis Research Group, to discuss the unique challenges faced by biotech companies in evidence generation, market access, and stakeholder engagement.

Genesis Research Group

- PMLiVE

Digital Transformation in the NHS’s 10-Year Plan: Techno-Optimism and the Limits of Efficiency

Here, Evelyne Priestman (Senior Consultant – HEOR) and Mary Baker (Senior Medical Writer) at Petauri Evidence explore the National Health Service (NHS) in England’s newly unveiled 10-year plan through the...

Petauri Evidence

- PMLiVE

AstraZeneca’s Imfinzi granted FDA priority review to treat early-stage gastric cancer

Gastric cancer is the fifth leading cause of cancer-related deaths globally

- PMLiVE

Roche shares promising data from Alzheimer’s disease development portfolio

The company is planning to initiate phase 3 studies of trontinemab in early AD this year

- PMLiVE

Bridging the gap: Should pharma step up as public health campaign funding declines?

With the decline in UK public health campaign funding, we have explored the unique opportunity presented to the pharmaceutical industry to step forward and do more to support the nation’s...

Say Communications

- PMLiVE

North East and North Cumbria NHS rolls out digital health platform to combat chronic kidney disease, affecting 1 in 10 UK adults

In a significant step towards tackling one of the UK’s most underdiagnosed conditions, North East and North Cumbria Integrated Care Board (ICB) has adopted the Healthinote digital health platform, providing...

Healthinote (by Cognitant)

- PMLiVE

AbbVie’s Elahere granted MHRA approval to treat platinum-resistant ovarian cancer

Approximately 7,500 people are diagnosed with ovarian cancer every year in the UK

- PMLiVE

J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma

The drug is already approved in the EU to treat relapsed or refractory cases of the blood cancer

- PMLiVE

Novartis and Matchpoint enter inflammatory disease partnership worth $1bn

The companies will focus on inflammatory diseases that have been historically difficult to treat

- PMLiVE

GSK’s Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma

More than 50,000 cases of the blood cancer are diagnosed in Europe each year

- PMLiVE

Sanofi and Kling Bio partner to accelerate discovery of neutralising antibodies

The alliance will centre on Kling’s B cell immortalisation and screening platform Kling-Select

- PMLiVE

Medscape Education Wins SILVER for Rare Disease Campaign

We are thrilled to announce that Medscape Education has been honored with the SILVER Award in the Patient Education Information division category by the 2025 National Health Information Awards! This...

Medscape Education

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links